Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial. Issue 17 (10th June 2021)

• Record Type: Journal Article
• Authors: Eriksson, Mikael; Eklund, Martin; Borgquist, Signe; Hellgren, Roxanna; Margolin, Sara; Thoren, Linda; Rosendahl, Ann; Lång, Kristina; Tapia, José; Bäcklund, Magnus; Discacciati, Andrea; Crippa, Alessio; Gabrielson, Marike; Hammarström, Mattias; Wengström, Yvonne; Czene, Kamila; Hall, Per
• Is Part Of: Journal of clinical oncology. Volume 39:Issue 17(2021)
• Page Start: 1899
• Page End: 1908
• Publication Date: 2021-06-10
• Subjects: Oncology -- Periodicals; Cancer -- Periodicals; Oncology; Medical Oncology; Cancérologie -- Périodiques; Cancer -- Périodiques; Cancérologie; Cancer; Oncology; Oncologia; Càncer; Periodicals; 616.994
• DOI: 10.1200/JCO.20.02598
• Languages: English
• ISSNs: 0732-183X

Abstract

Abstract : PURPOSE: Tamoxifen prevents breast cancer in high-risk women and reduces mortality in the adjuvant setting. Mammographic density change is a proxy for tamoxifen therapy response. We tested whether lower doses of tamoxifen were noninferior to reduce mammographic density and associated with fewer symptoms. PATIENTS AND METHODS: Women, 40-74 years of age, participating in the Swedish mammography screening program were invited to the 6-month double-blind six-arm randomized placebo-controlled noninferiority dose-determination KARISMA phase II trial stratified by menopausal status (EudraCT 2016-000882-22). In all, 1, 439 women were accrued with 1, 230 participants accessible for intention-to-treat analysis. The primary outcome was proportion of women treated with placebo, 1, 2.5, 5, and 10 mg whose mammographic density decreased at least as much as the median reduction in the 20 mg arm. The noninferior margin was 17%. Secondary outcome was reduction of symptoms. Post hoc analyses were performed by menopausal status. Per-protocol population and full population were analyzed in sensitivity analysis. RESULTS: The 1, 439 participants, 566 and 873 pre- and postmenopausal women, respectively, were recruited between October 1, 2016, and September 30, 2019. The participants had noninferior mammographic density reduction following 2.5, 5, and 10 mg tamoxifen compared with the median 10.1% decrease observed in the 20 mg group, a reduction confined to premenopausal women. Severe vasomotor symptoms (hot flashes, cold sweats, and night sweats) were reduced by approximately 50% in the 2.5, 5, and 10 mg groups compared with the 20 mg group. CONCLUSION: Premenopausal women showed noninferior magnitude of breast density decrease at 2.5 mg of tamoxifen, but fewer side effects compared with the standard dose of 20 mg. Future studies should test whether 2.5 mg of tamoxifen reduces the risk of primary breast cancer.